According to the UROMOL study, a comprehensive multi-institutional transcriptional analysis project aiming to classify NMIBC through molecular methods, Class 2 tumors frequently harbored HER2 mutations and were associated to the CIS pathway of progression, carrying higher progression rates to MIBC [97]. Here, ERBB2 is linked to in situ carcinoma.